Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paperTong‐Yuan Yang, Vibha Jawa, Manuela Braun et al.|Molecular Therapy — Methods & Clinical Development|2022Cited by 113
Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig<sup>TM</sup>) molecule that specifically and potently neutralizes both IL-1α and IL-1βSusan E. Lacy, Rajesh V. Kamath, Chengbin Wu et al.|mAbs|2015Cited by 57
Preexisting antibody assays for gene therapy: Considerations on patient selection cutoffs and companion diagnostic requirementsManuela Braun, Mark Milton, Claudia Lange et al.|Molecular Therapy — Methods & Clinical Development|2024Cited by 25
An IQ Consortium Perspective on Best Practices for Bioanalytical and Immunogenicity Assessment Aspects of CAR‐T and TCR‐T Cellular Therapies DevelopmentJochem Gokemeijer, Vibha Jawa, Nanda Balasubramanian et al.|Clinical Pharmacology & Therapeutics|2023Cited by 9
Immunogenicity Risk Assessment for Nucleic Acid Therapeutics: A Comprehensive Evaluation for ASO, siRNA, and Nonvaccine mRNA/LNP Therapies by the IQ ConsortiumJoanna Grudzinska‐Goebel, Vibha Jawa, Linzhi Chen et al.|Nucleic Acid Therapeutics|2025Cited by 6